Opioid Modulation of Oxytocin Release

Total Page:16

File Type:pdf, Size:1020Kb

Opioid Modulation of Oxytocin Release Review Opioid Modulation of Oxytocin Release Mark S. Morris, BA, Edward F. Domino, MD, and Steven E. Domino, MD Analgesia or anesthesia is frequently used for women in of a labor without sufficient cervical dilatation. This labor. A wide range of opioid analgesics with vastly differ- review discusses the scientific basis for opioid modulation ent pharmacokinetics, potencies, and potential side effects of oxytocin release from the posterior pituitary and the can be considered by physicians and midwives for labor- practical implications of this relationship to explain well- ing patients requesting pain relief other than a labor epi- known clinical observations of the effect of morphine on dural. The past 50 years have seen the use of the classic prodromal labor. mu opioid agonist morphine and other opioids diminish markedly for several reasons, including availability of Keywords: endogenous opioids; morphine; meperidine; epidural anesthetics, side effects, formulary restrictions, mu-kappa-delta opioid receptors; oxytocin; and concern for neonatal respiratory depression. Morphine parturition; vasopressin is now primarily used in obstetrics to provide rest and Journal of Clinical Pharmacology, 2010;50:1112-1117 sedation as appropriate for the stressed prodromal stages © 2010 The Author(s) he major hormone involved with parturition to system in modulating oxytocin release, it is of inter- Tstimulate uterine contractions is oxytocin. est to note the use of exogenous mu opioids such as Russell et al1 have reviewed the extensive literature morphine and meperidine in human parturition. on the complexity of the magnocellular oxytocin Different forms of analgesia/anesthesia are needed system. Endogenous opioids mechanisms inhibit for both the benefit of the woman in labor and her oxytocin release as part of the multiple hormones baby. In the United States today, about 1 in 3 women involved, including relaxin, estrogen, progesterone, and their caretakers are opting for cesarean sections, and autoinhibition by nitric oxide. typically as elective, scheduled surgery.2 The Cochrane Oxytocin is produced in the hypothalamus and is protocol for the use of parenteral opioids for mater- released into systemic circulation via the posterior nal pain relief in labor is especially useful.3 The lobe of the pituitary gland. Specifically, oxytocin is availability of a wide range of analgesics with vastly made in magnocellular neurosecretory cells of the different pharmacology, pharmacokinetics, milli- supraoptic nucleus and paraventricular nucleus of gram potencies, routes of administration, and side the hypothalamus. It is well established that oxy- effects is impressive. Nevertheless, morphine use tocin is involved in a positive feedback loop during during labor has had a checkered pro and con his- parturition, in which oxytocin causes uterine con- tory over the years. During its use to produce twi- tractions, which in turn lead to more oxytocin light sleep, it became clear that although analgesia release. This feed-forward loop continues until par- and amnesia for the mother was desirable, some turition. Oxytocin is also released when an infant women became excited and delirious. In addition, suckles at the nipple of a lactating mother and acts newborns frequently showed apnea. Thus, twilight at the mammary glands, causing milk letdown. In sleep was abandoned years ago. Its replacement view of the importance of the endogenous opioids with meperidine alone or in combination with pro- methazine also had a pro and con history of increased use to abandonment. Meperidine has a complex From the Departments of Pharmacology (Mr Morris, Dr E. F. Domino); pharmacology in addition to having mu opioid anal- and Obstetrics and Gynecology (Dr S. E. Domino), University of gesic properties. DeVoe et al4 reported that meperid- Michigan, Ann Arbor. Submitted for publication November 19, ine alone or in combination with promethazine, 2009; revised version accepted December 20, 2009. Address correspondence to S. E. Domino, MD, Department of Obstetrics and although analgesic, did not decrease but actually Gynecology, University of Michigan, Ann Arbor, MI 48109-5617; increased uterine activity over control from about 7 e-mail: [email protected]. to 20-30 Torr/min units of uterine activity over 10 to DOI:10.1177/0091270010361256 30 minutes. Many other opioids have been used 1112 •• JJ Clin Clin Pharmacol Pharmacol xxxx;xx:x-x 2010;50:1112-1117 OPIOID MODULATION OF OXYTOCIN RELEASE since, again with mixed results. Today, morphine is other published animal and human pituitary data used in a subset of obstetrical patients to provide that indicated negligible delta opioid binding. rest and sedation as appropriate for the stressed pro- Naltrindole has been found to bind to mu and kappa dromal stages of a labor without sufficient cervical in addition to delta receptors,11 which could account dilation with a fetus in no stress. This review pro- for the different conclusions. vides a rational scientific basis to its current use and shows why it is useful for more than just rest and Mu OPiOid MOdulaTiOn Of POsTeRiOR sedation for patients. PiTuiTaRy hORMOne Release OPiOid ReCePTORs in The PiTuiTaRy Opioid binding in the posterior pituitary is impor- tant because of the effect on oxytocin and vaso- Controversy exists over the nature of opiate binding in pressin release. Both mu and kappa opioid receptor the posterior pituitary.11 C-carfentanil (a selective mu agonists have been shown to affect posterior pitui- opioid receptor agonist) is known to have relatively tary hormone release. Oxytocin secretion is inhib- high binding potential in the human pituitary similar ited centrally by both mu and kappa agonists or to classical opiate binding areas in the brain, but its directly at the posterior pituitary via kappa recep- clinical significance remains unknown.5,6 However, tors. Lutz-Bucher and Koch12 isolated the rat neu- positron emission tomography (PET) imaging does not rointermediate as well as the neural lobe (posterior distinguish whether binding is in the anterior or pituitary). Removal of the endogenous opiate-rich posterior lobes. Relatively large doses of naloxone (1 mg/ pars intermedia cells from the pars nervosa enhanced kg) do not completely displace 11C-carfentanil binding both oxytocin and vasopressin release. Morphine in the pituitary compared to other brain areas, indicat- inhibited their release from both lobes, but the neu- ing the presence of a nonopioid binding site.5,6 One rointermediate lobe needed a larger concentration. possibility is that a metabolite of 11C-carfentanil such Naloxone reversed the effects of morphine, indicat- as 11C-methanol may be involved. ing a primarily mu opioid receptor action. Simantov and Snyder7 reported the presence Clarke and Patrick13 studied isolated rat pars ner- of mu opiate binding in bovine intermediate and vosa with attached pars intermedia. They electri- posterior but very little in the anterior pituitary, cally stimulated the pituitary stalk to measure where beta-endorphin is released.8 Jordan et al9 oxytocin and vasopressin release. Morphine inhib- studied postmortem pituitaries from 5 human par- ited both oxytocin and vasopressin release. Naloxone ticipants without neuroendocrine or neuronal dis- reversed morphine inhibition of oxytocin but not ease. They used (125I)-FK-33-824 for mu, (125I)[D.Ala2] vasopressin release. Bicknell et al14 found that oxy- Deltorphin-I for delta, and 3H-U69,593 for kappa tocin cells develop dependence with added mor- opioid sites. Quantitative in vitro autoradiography phine and eventually require morphine to function of pituitary sections with each radioactive ligand normally. When naloxone was given, the firing rate indicated the absence of significant labeling in the of oxytocin-secreting cells increased 360% and anterior lobe but high binding in the posterior pitui- plasma oxytocin levels increased 100 times greater tary. All 5 posterior pituitary specimens had signifi- than in controls. No significant difference was cant mu and kappa binding sites that almost overlap observed in vasopressin levels. Zhao et al15 also completely but had no significant delta binding found in rats that naloxone increased oxytocin sites. These investigators further showed that both release 100% and 173% in 2 experiments and vaso- the mu and kappa opioid binding was competitively pressin release only 30% and 20%, respectively. antagonized by other selective opioid ligands. The Pumford et al16 showed that morphine depresses more recent PET study by Weerts et al10 also demon- the firing rate of supraoptic oxytocin neurons when strated a specific mu opioid binding site in the given intracerebroventricularly (ICV) and intrave- human pituitary. These investigators studied mu as nously (IV). Both morphine tolerance and depend- well as delta opioid brain and pituitary binding in ence developed in magnocellular oxytocin neurons recently abstinent alcohol-dependent participants during 5 days of ICV infusion. The researchers sug- treated with naltrexone. The naltrexone-treated subjects gested that tolerance and dependence to endogenous had decreased binding in the pituitary for both opioids is important for oxytocin neurons during 11C-carfentanil (mu) and 11C-naltridole (delta). Delta pregnancy, in preparation for parturition. opioid binding in the human brain and pituitary was Ortiz-Miranda et al17,18 reported that mu opioid present but minimal. This latter finding differs from receptors modulate rat neurohypophyseal
Recommended publications
  • Oxytocin Is an Anabolic Bone Hormone
    Oxytocin is an anabolic bone hormone Roberto Tammaa,1, Graziana Colaiannia,1, Ling-ling Zhub, Adriana DiBenedettoa, Giovanni Grecoa, Gabriella Montemurroa, Nicola Patanoa, Maurizio Strippolia, Rosaria Vergaria, Lucia Mancinia, Silvia Coluccia, Maria Granoa, Roberta Faccioa, Xuan Liub, Jianhua Lib, Sabah Usmanib, Marilyn Bacharc, Itai Babc, Katsuhiko Nishimorid, Larry J. Younge, Christoph Buettnerb, Jameel Iqbalb, Li Sunb, Mone Zaidib,2, and Alberta Zallonea,2 aDepartment of Human Anatomy and Histology, University of Bari, 70124 Bari, Italy; bThe Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029; cBone Laboratory, The Hebrew University of Jerusalem, Jerusalem 91120, Israel; dGraduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, Miyagi 981-8555 Japan; and eCenter for Behavioral Neuroscience, Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30322 Communicated by Maria Iandolo New, Mount Sinai School of Medicine, New York, NY, February 19, 2009 (received for review October 24, 2008) We report that oxytocin (OT), a primitive neurohypophyseal hor- null mice (5). But the mice are not rendered diabetic, and serum mone, hitherto thought solely to modulate lactation and social glucose homeostasis remains unaltered (9). Thus, whereas the bonding, is a direct regulator of bone mass. Deletion of OT or the effects of OT on lactation and parturition are hormonal, actions OT receptor (Oxtr) in male or female mice causes osteoporosis that mediate appetite and social bonding are exerted centrally. resulting from reduced bone formation. Consistent with low bone The precise neural networks underlying OT’s central effects formation, OT stimulates the differentiation of osteoblasts to a remain unclear; nonetheless, one component of this network mineralizing phenotype by causing the up-regulation of BMP-2, might be the interactions between leptin- and OT-ergic neurones which in turn controls Schnurri-2 and 3, Osterix, and ATF-4 expres- in the hypothalamus (10).
    [Show full text]
  • The Opioid Epidemic: What Labs Have to Do with It?
    The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 1 Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 2 Analysis. Answers. Action. www.aphl.org Opiates and Opioids • Opiates vs. Opioids • Opiates: Naturally occurring, derived from the poppy plant • Opioids: “Opiate-like” drugs in effects, not chemical structure Includes opiates • Narcotic analgesics • CNS depressants • DEA Schedule I or II controlled substances • Additive effect with other CNS depressant drugs Analysis. Answers. Action. www.aphl.org Efficacy of Opioids • How do opioids work? • Bind with opioid receptors • Brain, spinal cord, GI tract, and throughout the body • Pain, emotion, breathing, movement, and digestion Opioid Receptor Analysis. Answers. Action. www.aphl.org Effects of Opioids Physiological Psychological • Pain relief • Drowsiness/ sedation • Cough suppression • Mental confusion • GI motility • Loss of memory • Respiratory depression • Lethargy/ apathy • Pupillary constriction • Euphoria/ tranquility • Itching • Mood swings • Constipation • Depression • Dependence • Withdrawal • Dependence Analysis. Answers. Action. www.aphl.org Opiates 1 Opiates • Naturally occurring alkaloids Opium • Latex from the opium poppy plant Codeine: • Mild to moderate pain • Antitussive Morphine: • Severe pain • Metabolite of codeine and heroin Analysis. Answers. Action. www.aphl.org Opiates 2 Semi-synthetic Opiates: • Synthesized from a natural opiate Heroin: • Schedule I narcotic Hydrocodone (Vicodin): • Mild to moderate pain • Metabolizes to hydromorphone (Dilaudid) Oxycodone (Oxycontin/Percocet): • Moderate to severe pain • Metabolizes to oxymorphone (Opana) Analysis. Answers. Action.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • A Review of Unique Opioids and Their Conversions
    A Review of Unique Opioids and Their Conversions Jacqueline Cleary, PharmD, BCACP Assistant Professor Albany College of Pharmacy and Health Sciences Adjunct Professor SAGE College of Nursing DISCLOSURES • Kaleo • Remitigate, LLC OBJECTIVES • Compare and contrast unique pharmacotherapy options for the treatment of chronic pain including: methadone, buprenoprhine, tapentadol, and tramadol • Select methadone, buprenorphine, tapentadol, or tramadol based on patient specific factors • Apply appropriate opioid conversion strategies to unique opioids • Understand opioid overdose risk surrounding opioid conversions and the use of unique opioids UNIQUE OPIOIDS METHADONE, BUPRENORPHINE, TRAMADOL, TAPENTADOL METHADONE My favorite drug because….? METHADONE- INDICATIONS • FDA labeled indications – (1) chronic pain (2) detoxification Oral soluble tablets for suspension NOT indicated for chronic pain treatment • Initial inpatient detoxification of opioids by a licensed trained provider with methadone and supportive care is appropriate • Methadone maintenance provider must have special credentialing and training as required by state Outpatient prescription must be for pain ONLY and say “for pain” on RX • Continuation of methadone maintenance from outside provider while patient is inpatient for another condition is appropriate http://cdn.atforum.com/wp-content/uploads/SAMHSA-2015-Guidelines-for-OTPs.pdf MECHANISM OF ACTION • Potent µ-opioid agonist • NMDA receptor antagonist • Norepinephrine reuptake inhibitor • Serotonin reuptake inhibitor ADVERSE EVENTS
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Oxytocin Effects in Mothers and Infants During Breastfeeding
    © 2013 SNL All rights reserved REVIEW Oxytocin effects in mothers and infants during breastfeeding Oxytocin integrates the function of several body systems and exerts many effects in mothers and infants during breastfeeding. This article explains the pathways of oxytocin release and reviews how oxytocin can affect behaviour due to its parallel release into the blood circulation and the brain. Oxytocin levels are higher in the infant than in the mother and these levels are affected by mode of birth. The importance of skin-to-skin contact and its association with breastfeeding and mother-infant bonding is discussed. Kerstin Uvnäs Moberg Oxytocin – a system activator increased function of inhibitory alpha-2 3 MD, PhD xytocin, a small peptide of just nine adrenoceptors . Professor of Physiology amino acids, is normally associated The regulation of the release of oxytocin Swedish University of Agriculture O with labour and the milk ejection reflex. is complex and can be affected by different [email protected] However, oxytocin is not only a hormone types of sensory inputs, by hormones such Danielle K. Prime but also a neurotransmitter and a as oestrogen and even by the oxytocin 1,2 molecule itself. This article will focus on PhD paracrine substance in the brain . During Breastfeeding Research Associate breastfeeding it is released into the brain of four major sensory input nervous Medela AG, Baar, Switzerland both mother and infant where it induces a pathways (FIGURES 2 and 3) activated by: great variety of functional responses. 1. Sucking of the mother’s nipple, in which Through three different release pathways the sensory nerves originate in the (FIGURE 1), oxytocin functions rather like a breast.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Opioid & Other Drug Overdose Syndromic Surveillance Report
    Opioid & Other Drug Overdose Syndromic Surveillance Report Suspected Unintentional Overdose Visits Past 14 Weeks Week Starting # of Visits 7-Week Ave. Alerts (1-Week Lag) 6/20/21 32 33.0 None 6/27/21 39 33.4 None 7/4/21 27 36.0 None 7/11/21 35 35.1 None 7/18/21 31 35.9 None 7/25/21 38 34.6 None 8/1/21 26 33.7 None 8/8/21 37 32.6 None 8/15/21 30 33.3 None 8/22/21 31 32.0 None 8/29/21 24 32.6 None 9/5/21 33 31.0 None 9/12/21 22 31.3 None 9/19/21 26 29.0 None Date report produced: 27-Sep-2021 Notes. Includes all patients 10 years and older visiting ALL Simcoe Muskoka Hospitals. Opioid and/or Toxicity related visits with a CTAS score of 1, 2, 3 or missing. Alerts are generated using the CDC EARS CUSUM Algorithm. C1 uses a 7-Week baseline with a one-Week lag. Participating Hospitals. Muskoka Algonquin Healthcare – Bracebridge (BRSH) & Muskoka Algonquin Healthcare – Huntsville (HUSH); Georgian Bay General Hospital (GBGH) & Orillia Soldiers Memorial Hospital (OSMH); Royal Victoria Regional Health Centre (RVH); Stevenson Memorial Hospital (SVMH); Collingwood General and Marine Hospital (CGMH). Data Source. Acute Care Enhanced Surveillance (ACES): a real-time syndromic surveillance system developed and maintained by Kingston, Frontenac and Lennox and Addington (KFL&A) Public Health and funded by the Ministry of Health and Long Term Care (http://www.kflaphi.ca/acute-care-enhanced-surveillance/).
    [Show full text]
  • Physiology of Hypothalamus and Pituitary
    Physiology of Hypothalamus and Pituitary Simge Aykan, PhD Department of Physiology Ankara University School of Medicine Pituitary Gland • Pituitary gland (hypophysis) is two different tissue types that merged during embryonic development • Anterior pituitary (adenohypophysis): true endocrine gland of epithelial origin • Posterior pituitary (neurohypophysis): extension of the neural tissue of the brain • secretes neurohormones made in the hypothalamus Pituitary Gland • Pituitary bridges and integrates the neural and endocrine mechanisms of homeostasis. • Highly vascular • Posterior pituitary receives arterial blood • anterior pituitary receives only portal venous inflow from the median eminence. • Portal system is particularly important in its function of carrying neuropeptides from the hypothalamus and pituitary stalk to the anterior pituitary. Posterior Pituitary • Storage and release site for two neurohormones (peptide hormones) • Oxytocin • Vasopressin (antidiuretic hormone; ADH) • Large diameter neurons producing hormones are clustered in hypothalamus at paraventricular (oxytocin) and supraoptic nuclei (ADH) • Secretory vesicles containing neurohormones transported to posterior pituitary through axons of the neurons • Stored at the axons until a release signal arrives • Depolarization of the axon terminal opens voltage gated Ca2+ channels and exocytosis is triggered • Hormones release to the circulation Posterior Pituitary • The posterior pituitary regulates water balance and uterine contraction • Vasopressin (ADH), is a neuropeptide
    [Show full text]
  • Opioid Receptors in Immune and Glial Cells—Implications for Pain Control
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Institutional Repository of the Freie Universität Berlin REVIEW published: 04 March 2020 doi: 10.3389/fimmu.2020.00300 Opioid Receptors in Immune and Glial Cells—Implications for Pain Control Halina Machelska* and Melih Ö. Celik Department of Experimental Anesthesiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany Opioid receptors comprise µ (MOP), δ (DOP), κ (KOP), and nociceptin/orphanin FQ (NOP) receptors. Opioids are agonists of MOP, DOP, and KOP receptors, whereas nociceptin/orphanin FQ (N/OFQ) is an agonist of NOP receptors. Activation of all four opioid receptors in neurons can induce analgesia in animal models, but the most clinically relevant are MOP receptor agonists (e.g., morphine, fentanyl). Opioids can also affect the function of immune cells, and their actions in relation to immunosuppression and infections have been widely discussed. Here, we analyze the expression and the role of opioid receptors in peripheral immune cells and glia in the modulation of pain. All four opioid receptors have been identified at the mRNA and protein levels in Edited by: immune cells (lymphocytes, granulocytes, monocytes, macrophages) in humans, rhesus Sabita Roy, monkeys, rats or mice. Activation of leukocyte MOP, DOP, and KOP receptors was University of Miami, United States recently reported to attenuate pain after nerve injury in mice. This involved intracellular Reviewed by: 2+ Lawrence Toll, Ca -regulated release of opioid peptides from immune cells, which subsequently Florida Atlantic University, activated MOP, DOP, and KOP receptors on peripheral neurons.
    [Show full text]
  • Changes in Spinal and Opioid Systems in Mice Deficient in The
    The Journal of Neuroscience, November 1, 2002, 22(21):9210–9220 Changes in Spinal ␦ and ␬ Opioid Systems in Mice Deficient in the A2A Receptor Gene Alexis Bailey,1 Catherine Ledent,2 Mary Kelly,1 Susanna M. O. Hourani,1 and Ian Kitchen1 1Pharmacology Group, School of Biomedical and Life Sciences, University of Surrey, Guildford, Surrey, GU2 7XH United Kingdom, and 2Institut de Recherche Interdisciplinaire en Biologie Humaine et Nucle´ aire, Universite´ Libre de Bruxelles, B-1070 Brussels, Belgium A large body of evidence indicates important interactions be- but not in the brains of the knock-out mice. ␮ and ORL1 receptor tween the adenosine and opioid systems in regulating pain at both expression were not altered significantly. Moreover, a significant ␦ the spinal and supraspinal level. Mice lacking the A2A receptor reduction in -mediated antinociception and a significant increase gene have been developed successfully, and these animals were in ␬-mediated antinociception were detected in mutant mice, shown to be hypoalgesic. To investigate whether there are any whereas ␮-mediated antinociception was unaffected. Comparison compensatory alterations in opioid systems in mutant animals, we of basal nociceptive latencies showed a significant hypoalgesia in have performed quantitative autoradiographic mapping of ␮, ␦, ␬, knock-out mice when tested at 55°C but not at 52°C. The results and opioid receptor-like (ORL1) opioid receptors in the brains and suggest a functional interaction between the spinal ␦ and ␬ opioid spinal cords of wild-type and homozygous A2A receptor knock- and the peripheral adenosine system in the control of pain out mice. In addition, ␮-, ␦-, and ␬Ϫmediated antinociception pathways. using the tail immersion test was tested in wild-type and homozy- ␮ ␦ gous A2A receptor knock-out mice.
    [Show full text]
  • SAMHSA Opioid Overdose Prevention TOOLKIT
    SAMHSA Opioid Overdose Prevention TOOLKIT Opioid Use Disorder Facts Five Essential Steps for First Responders Information for Prescribers Safety Advice for Patients & Family Members Recovering From Opioid Overdose TABLE OF CONTENTS SAMHSA Opioid Overdose Prevention Toolkit Opioid Use Disorder Facts.................................................................................................................. 1 Scope of the Problem....................................................................................................................... 1 Strategies to Prevent Overdose Deaths.......................................................................................... 2 Resources for Communities............................................................................................................. 4 Five Essential Steps for First Responders ........................................................................................ 5 Step 1: Evaluate for Signs of Opioid Overdose ................................................................................ 5 Step 2: Call 911 for Help .................................................................................................................. 5 Step 3: Administer Naloxone ............................................................................................................ 6 Step 4: Support the Person’s Breathing ........................................................................................... 7 Step 5: Monitor the Person’s Response ..........................................................................................
    [Show full text]